vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Xiao-I Corp (AIXI). Click either name above to swap in a different company.

Xiao-I Corp is the larger business by last-quarter revenue ($11.5M vs $8.1M, roughly 1.4× Arcellx, Inc.). Xiao-I Corp runs the higher net margin — -263.9% vs -766.0%, a 502.2% gap on every dollar of revenue.

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.

ACLX vs AIXI — Head-to-Head

Bigger by revenue
AIXI
AIXI
1.4× larger
AIXI
$11.5M
$8.1M
ACLX
Higher net margin
AIXI
AIXI
502.2% more per $
AIXI
-263.9%
-766.0%
ACLX

Income Statement — Q1 FY2025 vs Q2 FY2025

Metric
ACLX
ACLX
AIXI
AIXI
Revenue
$8.1M
$11.5M
Net Profit
$-62.3M
$-30.4M
Gross Margin
58.1%
Operating Margin
-847.6%
-254.9%
Net Margin
-766.0%
-263.9%
Revenue YoY
-79.3%
Net Profit YoY
-765.1%
EPS (diluted)
$-1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
AIXI
AIXI
Q2 25
$11.5M
Q1 25
$8.1M
Q4 24
$15.3M
Q3 24
$26.0M
Q2 24
$27.4M
$33.0M
Q1 24
$39.3M
Q4 23
$63.1M
Q3 23
$15.0M
Net Profit
ACLX
ACLX
AIXI
AIXI
Q2 25
$-30.4M
Q1 25
$-62.3M
Q4 24
$-47.1M
Q3 24
$-25.9M
Q2 24
$-27.2M
$-15.5M
Q1 24
$-7.2M
Q4 23
$19.8M
Q3 23
$-39.3M
Gross Margin
ACLX
ACLX
AIXI
AIXI
Q2 25
58.1%
Q1 25
Q4 24
Q3 24
Q2 24
64.5%
Q1 24
Q4 23
Q3 23
Operating Margin
ACLX
ACLX
AIXI
AIXI
Q2 25
-254.9%
Q1 25
-847.6%
Q4 24
-348.2%
Q3 24
-129.1%
Q2 24
-127.8%
-45.0%
Q1 24
-40.3%
Q4 23
23.8%
Q3 23
-299.9%
Net Margin
ACLX
ACLX
AIXI
AIXI
Q2 25
-263.9%
Q1 25
-766.0%
Q4 24
-308.4%
Q3 24
-99.4%
Q2 24
-99.3%
-47.2%
Q1 24
-18.3%
Q4 23
31.4%
Q3 23
-263.0%
EPS (diluted)
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
$-1.13
Q4 24
$-0.87
Q3 24
$-0.48
Q2 24
$-0.51
$-0.64
Q1 24
$-0.14
Q4 23
$0.42
Q3 23
$-0.81

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
AIXI
AIXI
Cash + ST InvestmentsLiquidity on hand
$543.3M
$5.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
Total Assets
$648.1M
$82.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
AIXI
AIXI
Q2 25
$5.0M
Q1 25
$543.3M
Q4 24
$587.4M
Q3 24
$574.3M
Q2 24
$516.7M
$1.8M
Q1 24
$573.9M
Q4 23
$702.0M
Q3 23
$439.7M
Stockholders' Equity
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
$416.9M
Q4 24
$454.8M
Q3 24
$483.0M
Q2 24
$487.2M
Q1 24
$496.6M
Q4 23
$485.4M
Q3 23
$266.1M
Total Assets
ACLX
ACLX
AIXI
AIXI
Q2 25
$82.4M
Q1 25
$648.1M
Q4 24
$711.3M
Q3 24
$764.9M
Q2 24
$734.3M
$87.6M
Q1 24
$779.7M
Q4 23
$825.1M
Q3 23
$614.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
AIXI
AIXI
Operating Cash FlowLast quarter
$-63.1M
$-2.3M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
AIXI
AIXI
Q2 25
$-2.3M
Q1 25
$-63.1M
Q4 24
$-46.0M
Q3 24
$30.7M
Q2 24
$-36.2M
Q1 24
$-31.9M
Q4 23
$58.2M
Q3 23
$-10.1M
Free Cash Flow
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
Q2 24
$-39.5M
Q1 24
$-38.3M
Q4 23
$53.0M
Q3 23
$-18.0M
FCF Margin
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
Q2 24
-144.1%
Q1 24
-97.7%
Q4 23
83.9%
Q3 23
-120.5%
Capex Intensity
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
Q2 24
11.7%
Q1 24
16.4%
Q4 23
8.4%
Q3 23
53.0%
Cash Conversion
ACLX
ACLX
AIXI
AIXI
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
2.94×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons